Kleve, Germany

Peter Scholz


 

 

Average Co-Inventor Count = 11.3

ph-index = 2

Forward Citations = 24(Granted Patents)


Location History:

  • Köln, DE (2013)
  • Cologne, DE (2017)
  • Kleve, DE (2013 - 2018)

Company Filing History:


Years Active: 2013-2018

where 'Filed Patents' based on already Granted Patents

5 patents (USPTO):

Title: The Innovations of Inventor Peter Scholz

Introduction: Peter Scholz is a distinguished inventor based in Kleve, Germany, known for his significant contributions to biotechnology. With a total of five patents to his name, Scholz has focused his research on developing innovative solutions in the field of monoclonal antibodies and their applications in medical treatments.

Latest Patents: Among his most recent innovations, Scholz has developed optimized monoclonal antibodies against the tissue factor pathway inhibitor (TFPI). These isolated monoclonal antibodies are designed to bind specifically to human TFPI, which plays a critical role in the coagulation process. His patent also covers isolated nucleic acid molecules that encode these antibodies, pharmaceutical compositions that utilize these antibodies, and methods to produce them. Additionally, he has worked on antibodies that bind to tumor necrosis factor alpha (TNF-α), including nucleic acids and vectors related to their development.

Career Highlights: Throughout his career, Peter Scholz has held positions at prominent organizations, including Bayer Healthcare LLC and Bayer Pharma Aktiengesellschaft. His work in these companies has significantly influenced advancements in therapeutic antibody development and production methodologies.

Collaborations: Scholz has collaborated with notable professionals in the field, such as Christian Votsmeier and Susanne Steinig. These partnerships have fostered a robust exchange of ideas and research, leading to the successful development of various patentable technologies.

Conclusion: Peter Scholz's contributions to the field of biotechnology illustrate his commitment to innovation and research excellence. His patents not only reflect his inventive spirit but also have the potential to impact the medical industry significantly, improving treatments for conditions related to coagulation and inflammation. As he continues his work, Scholz remains a key figure in the advancement of therapeutic technologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…